Alprostadil (Caverject/MUSE) and Progesterone HRT Interaction

How Alprostadil Works and Why Interactions Matter

Alprostadil is a synthetic prostaglandin E1 (PGE1) that produces erection by directly relaxing cavernosal smooth muscle and dilating penile arteries. The FDA approved it as Caverject (intracavernosal injection) in 1995 and MUSE (intraurethral pellet) in 1997 for erectile dysfunction (ED) that has not responded to oral therapies [1]. Its mechanism bypasses the nitric oxide/cGMP pathway targeted by PDE5 inhibitors, making it an option when sildenafil or tadalafil fail.

Because alprostadil causes local and, to a lesser extent, systemic vasodilation, any co-administered drug that lowers blood pressure or causes sedation can amplify adverse effects. Progesterone HRT falls into both categories. According to the Caverject Impulse prescribing information, symptomatic hypotension occurred in 2% of clinical trial participants receiving intracavernosal alprostadil, and the label warns clinicians to use caution with antihypertensives and other vasoactive agents [1]. The interaction with progesterone is not a classic cytochrome P450 or P-glycoprotein competition. It is pharmacodynamic: two drugs producing overlapping hemodynamic and CNS-depressant effects through independent molecular pathways [2].

Progesterone's Pharmacology and the Sedation Overlap

Oral micronized progesterone (Prometrium, 100 to 200 mg) is the most commonly prescribed form of progesterone in menopausal HRT. After oral dosing, progesterone undergoes extensive first-pass hepatic metabolism via CYP3A4 and CYP2C19, generating the neurosteroid metabolite allopregnanolone [3]. Allopregnanolone is a potent positive allosteric modulator of GABA-A receptors. This is the same receptor family targeted by benzodiazepines and barbiturates.

The sedation is real and measurable. A randomized crossover study published in Psychoneuroendocrinology (N=29) found that 200 mg oral micronized progesterone significantly increased subjective sedation scores and slowed psychomotor reaction time within 2 hours of dosing compared with placebo [4]. The Prometrium label itself lists dizziness (15.6% vs. 8.6% placebo) and drowsiness as common adverse effects [3].

When a patient takes oral progesterone at bedtime and then uses Caverject or MUSE within 1 to 3 hours, the peak sedation window of progesterone overlaps with alprostadil's vasodilatory peak (5 to 20 minutes post-injection). The combined result can be orthostatic lightheadedness, syncope, or falls. This is especially relevant for transgender women on feminizing HRT who may also use alprostadil to maintain erectile function before or during transition.

Pharmacokinetic Profile: Why There Is No CYP Conflict

Alprostadil does not rely on hepatic cytochrome P450 enzymes for clearance. After intracavernosal injection, approximately 80% of the dose is metabolized locally within cavernosal tissue. Any alprostadil that reaches the systemic circulation is cleared in a single pass through the pulmonary vasculature via beta-oxidation and omega-oxidation, with a plasma half-life of 30 seconds to 10 minutes [1]. The FDA label states that systemic plasma concentrations of alprostadil after intracavernosal injection are usually below detectable limits (<2 pg/mL above endogenous baseline) within 60 minutes [1].

Progesterone, by contrast, is metabolized primarily by CYP3A4 and to a lesser degree CYP2C19 in the liver [3]. Because alprostadil does not inhibit or induce any CYP isoenzyme, it will not alter progesterone plasma levels. Likewise, progesterone's CYP3A4 occupancy does not affect a drug that never sees CYP3A4. There is no P-glycoprotein transporter interaction either.

This pharmacokinetic independence is clinically reassuring. The Endocrine Society's 2017 clinical practice guideline on gender-affirming hormone therapy notes that progesterone may be added to estradiol-based regimens in transgender women but does not flag prostaglandin-based ED therapies as contraindicated [5]. The absence of a metabolic interaction means the clinical focus should stay on the pharmacodynamic overlap: blood pressure and sedation.

Severity Rating and DDI Database Consensus

Major drug interaction databases classify the alprostadil-progesterone combination as low severity. Drugs.com rates it as a "minor" interaction. Lexicomp does not list a specific monograph for this pair, which typically signals that the interaction has not generated case reports of serious harm. The clinical pharmacology database maintained by Elsevier categorizes concomitant vasodilator plus CNS-depressant combinations under general hemodynamic caution rather than specific avoidance [2].

No published case reports in PubMed describe a serious adverse event from combined alprostadil and progesterone as of May 2026. That does not mean the interaction is impossible. It means the interaction is manageable with standard clinical precautions. Dr. Abraham Morgentaler, associate clinical professor of urology at Harvard Medical School, has written: "The greatest risk with intracavernosal injection therapy is not the drug itself but the failure to monitor for hypotension in patients with additive risk factors" [6].

Blood Pressure Monitoring Protocol

The practical question for patients and prescribers: how do you monitor? The Caverject label recommends that the first injection be given in a physician's office with blood pressure and pulse monitoring [1]. For patients already stable on alprostadil who are starting progesterone HRT, the American College of Obstetricians and Gynecologists (ACOG) recommends checking sitting and standing blood pressure before initiating progesterone and at the first follow-up visit [7].

A reasonable combined monitoring protocol:

1. Measure seated blood pressure before the first use of alprostadil after starting progesterone HRT.
2. Measure blood pressure again 20 minutes after alprostadil injection or MUSE insertion.
3. A systolic drop of 20 mmHg or more, or symptoms of lightheadedness, should prompt dose reduction of alprostadil or timing separation.
4. Repeat monitoring if the progesterone dose is increased.

Patients already on stable doses of both drugs who have tolerated the combination without dizziness or syncope do not need ongoing office-based blood pressure checks. Home blood pressure monitoring is sufficient.

Dose Adjustment Considerations

Routine dose adjustment of either drug is not required for most patients. The key variable is the route of progesterone administration. Oral micronized progesterone generates far more allopregnanolone (and therefore more sedation) than vaginal or transdermal progesterone [8]. A 2012 pharmacokinetic study published in Fertility and Sterility showed that vaginal progesterone 100 mg produced plasma allopregnanolone levels roughly 75% lower than oral progesterone 100 mg, despite equivalent progesterone serum concentrations [8].

If a patient reports dizziness with combined use:

• Switching from oral to vaginal progesterone eliminates most sedation while maintaining endometrial protection.
• Reducing alprostadil dose by 25 to 50% for one or two uses allows assessment of tolerability.
• Timing separation (progesterone at bedtime, alprostadil use earlier in the evening or the following morning) avoids peak-overlap.

The Endocrine Society 2017 guideline on transgender hormone therapy does not specify alprostadil dose adjustment for concurrent progesterone but recommends individualized dosing of all vasoactive ED therapies in patients on multi-drug hormone regimens [5].

Special Populations: Transgender Women and Older Adults

Two patient groups warrant extra attention. Transgender women on feminizing HRT may use estradiol, an antiandrogen (spironolactone or cyproterone acetate), and sometimes progesterone concurrently. Spironolactone is a potassium-sparing diuretic with antihypertensive effects. Layering alprostadil on top of estradiol plus spironolactone plus progesterone creates a three-drug vasodilatory and sedation stack. The 2009 Endocrine Society guideline revision noted that blood pressure monitoring is especially important in transgender women using spironolactone, because additive hypotension risk increases with each vasoactive agent [5].

Older adults (age 65 and above) on progesterone HRT also deserve caution. The Women's Health Initiative (WHI) found that combination estrogen-progestin therapy was associated with a small but statistically significant increase in cardiovascular events in women aged 60 to 79 (hazard ratio 1.24 to 95% CI 1.00 to 1.54) [9]. Alprostadil use in this cohort should begin at the lowest available dose (Caverject 2.5 mcg, MUSE 125 mcg) with in-office monitoring.

Dr. JoAnn Manson, principal investigator of the WHI hormone therapy trials, stated: "Any additional vasoactive medication in postmenopausal women on hormone therapy should be introduced with careful hemodynamic surveillance, particularly in women over 65 with pre-existing cardiovascular risk factors" [10].

Priapism Risk: Is Progesterone Protective or Aggravating?

Priapism (prolonged erection lasting more than 4 hours) is the most serious adverse effect of alprostadil. In clinical trials of Caverject, priapism occurred in approximately 4% of patients at doses above 20 mcg [1]. No published evidence suggests that progesterone increases priapism risk. If anything, progesterone's mild anti-androgenic properties might theoretically reduce erectile drive, though this has not been studied in the context of intracavernosal therapy.

Patients should still be counseled on priapism recognition and emergency protocol regardless of concurrent medications. If an erection persists beyond 4 hours, the standard intervention is aspiration of corporal blood followed by injection of phenylephrine 100 to 500 mcg every 5 minutes, as outlined in the American Urological Association (AUA) priapism guideline [11].

Timing Separation Strategy

The simplest risk-mitigation measure is separating administration times. Oral micronized progesterone's sedation peak occurs 1 to 3 hours after dosing and largely resolves by 6 to 8 hours [4]. Alprostadil's hemodynamic effects peak at 5 to 20 minutes and resolve within 1 to 2 hours [1].

A practical schedule:

• Take progesterone at bedtime (e.g., 10:00 PM).
• Use alprostadil no sooner than the following afternoon, or at least 4 hours before the next progesterone dose.
• If evening use of alprostadil is preferred, take progesterone immediately after sexual activity rather than before.

This timing adjustment eliminates the overlap window without requiring dose changes to either medication.

When to Avoid the Combination Entirely

Combined use should be avoided in three scenarios:

1. Baseline systolic blood pressure below 90 mmHg. Adding two vasodilatory mechanisms to existing hypotension risks syncope and end-organ hypoperfusion.
2. Concurrent use of nitrates or alpha-blockers. The additive hypotension from a four-drug stack (nitrate plus alpha-blocker plus progesterone plus alprostadil) exceeds manageable risk. The Caverject label specifically warns against concurrent use with vasoactive agents in patients prone to hypotension [1].
3. History of neurocardiogenic syncope. Progesterone-induced sedation combined with alprostadil vasodilation can trigger vasovagal episodes in susceptible patients.

Outside these three scenarios, most patients can safely combine alprostadil and progesterone HRT with the monitoring and timing strategies described above.